GLP-1 and kidney function — research to date has not established a direct harmful effect of these medications on kidney tissue, and most of the kidney-related events documented in exenatide case reports were attributed to an indirect dehydration pathway. A 2015 review of exenatide case reports found that most kidney-related adverse events were attributed to pre-renal causes: nausea, vomiting, and reduced fluid intake that may reduce blood flow to the kidneys. This page covers what kidneys do, what those reports observed in specific study populations, and what you can log and discuss with your provider.
What Your Kidneys Actually Do
Your kidneys are two fist-sized organs located in the back of the abdominal cavity. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), kidneys filter your blood, removing waste and extra fluid from your body. This filtering process runs continuously, keeping the balance of fluids, electrolytes, and waste products within a range the body can work with.
Beyond filtering, kidneys play several other roles: they help regulate blood pressure, produce hormones that signal the body to produce red blood cells, and activate a form of vitamin D important for bone health. When kidneys are not filtering the way they should, waste and extra fluid can accumulate and begin to affect how other systems in the body function.
The NIDDK estimates that more than 35 million U.S. adults — more than 1 in every 7 — live with chronic kidney disease (CKD). Many of them do not know it, because CKD often develops without noticeable symptoms in its early stages. This is one reason why kidney function tends to be monitored for people managing conditions such as type 2 diabetes or high blood pressure, both of which can affect kidney health over time.
Two blood tests and one urine test that providers commonly use to assess kidney function are:
- eGFR (estimated glomerular filtration rate): A calculation derived from a blood creatinine level, along with age and other factors. It estimates how much blood your kidneys filter per minute. Your provider interprets what your number means relative to your history.
- Serum creatinine: A waste product that healthy kidneys continuously clear from the blood. When kidney filtering slows, creatinine may accumulate. Interpretation depends on your individual baseline, body composition, and other clinical factors.
- Urine albumin-to-creatinine ratio (uACR): A urine test that checks whether protein is leaking into urine — a possible indicator that the kidney's filtering membranes are under stress.
None of these tests, in isolation, tells you that something is or is not wrong. What they measure is well defined; what they mean in your particular case is your provider's call.
What Researchers Have Observed So Far
Research on GLP-1 medications and kidney health is still developing, and the published picture is incomplete. Most of what is currently available comes from studies of specific medications and specific populations, so generalizing broadly from these findings requires care.
A 2015 review by Filippatos TD, Panagiotopoulou TV, and Elisaf MS, published in the Review of Diabetic Studies, examined a pooled analysis of 5,594 participants from 19 randomized, controlled clinical trials of exenatide twice-daily. The review noted that exenatide had been associated with the development of acute kidney injury in approximately 100 case reports.
In most of those reports, the acute kidney injury was attributed to pre-renal causes: exenatide-induced nausea and vomiting, reduced fluid intake, and significant fluid loss — not to a direct effect on kidney tissue. The review also found that most individuals who experienced deterioration of kidney function had at least one pre-existing risk factor, such as cardiac failure, hypertension, or use of other medications that can affect kidney health.
Several things are worth keeping in mind when reading this evidence:
- The 2015 review focused specifically on exenatide, one GLP-1 medication. Findings from exenatide studies cannot be automatically applied to all GLP-1 medications or all people who use them.
- This review was published in 2015. The GLP-1 medication landscape has changed substantially since then, and newer research continues to be published.
- Observations in a clinical trial population describe what was measured in those participants under those study conditions. Individual experience varies.
- The review cites a pooled analysis that found renal impairment-related adverse events to be rare — at 1.6 per 100 person-years in both the exenatide and comparator groups, with no significant difference observed between them — though rarity in a trial population does not rule out relevance for individuals with specific risk profiles.
If you have pre-existing kidney disease, cardiovascular conditions, or take other medications that may interact with kidney function, discussing what kidney monitoring looks like in your care plan is a reasonable conversation to have with your provider before and during GLP-1 treatment.
The Indirect Route: Dehydration and Kidney Strain
The most commonly discussed connection between GLP-1 medications and kidney concerns is an indirect one. The GI side effects associated with this class of medications — particularly nausea, vomiting, and diarrhea — can lead to significant fluid loss in some people. Severe or sustained fluid loss is a known stressor for kidney function in any context, because kidneys rely on adequate blood flow and circulating fluid to filter effectively. When fluid levels drop substantially, kidneys may receive reduced blood flow, which can change how well they filter. This is referred to as pre-renal stress: the pressure originates in the body's fluid balance, not within the kidney itself.
This is the pathway that the 2015 review identified as the most common explanation for kidney-related events in exenatide case reports. It also means the practical response centers on managing fluid intake and reporting significant GI symptoms promptly — not on the medication's direct renal chemistry.
For a full look at what side effects are worth reporting and when, including the threshold for contacting your care team, see our guide on when to reach out about GLP-1 side effects. For practical approaches to staying hydrated while navigating GLP-1 side effects, hydration tips for people on GLP-1 medications covers that in detail.
The kidney connection here runs through fluid balance, not through a direct effect on kidney tissue. Managing nausea and staying adequately hydrated — and telling your provider when GI symptoms feel hard to manage — are the practical handles on this indirect route.
What Is Worth Logging Between Appointments
Tracking does not mean diagnosing. The goal of logging information about how you feel between appointments is to give your provider more specific, useful material to work with — not to arrive at a conclusion on your own.
The categories below describe things people find helpful to note. You do not need to track all of them, and what is worth your attention depends on your individual situation and what your provider has asked you to watch for.
| Category | What to Note |
|---|---|
| Fluid intake | Whether your daily intake has felt lower than usual; days when nausea made drinking difficult |
| GI symptoms | Episodes of vomiting or diarrhea, roughly how many, and how long they lasted |
| Urine changes | Noticeable changes in color, amount, or frequency — described in plain terms, not interpreted |
| Energy level | Unusual fatigue that feels different from your normal baseline |
| Swelling | Any new or increasing swelling in feet, ankles, or lower legs |
| Lab results | Dates of your last kidney function tests and what your provider said about them |
A few practical notes on logging:
Specificity matters more than volume. "I vomited three times on Tuesday and once on Wednesday, each time in the morning" is more useful than "I had nausea this week." Providers can work with duration, frequency, and pattern in ways they cannot with general impressions.
You do not need to have a conclusion when you bring these notes to an appointment. Describing what you have observed and asking what it means is a legitimate and often underused approach to shared decision-making.
If you are managing type 2 diabetes alongside your GLP-1 medication, kidney function monitoring may already be part of your broader diabetes care. Our guide on what to track when managing type 2 diabetes on a GLP-1 medication covers the overlap in more depth.
If you would like a place to record these observations between appointments, The GLP-1 Journal's free symptom and progress tracker runs in your browser with no account required — your entries stay on your device.
Bringing It Up With Your Provider
Many people are uncertain how to bring up kidney concerns in a short appointment, especially when they are not sure whether what they have noticed is significant. The most useful framing is usually descriptive: what you observed, when, for how long. You do not need to come in with a diagnosis or a concern that is fully formed.
A few questions that tend to open the conversation:
- "Should my kidney function be monitored while I am on this medication, and if so, how is that decision made?"
- "What do my current eGFR or creatinine levels mean for how we are managing my care?"
- "Is my existing kidney history something that changes how we approach this medication?"
- "If I notice significant changes in how much I am urinating, or new swelling, when should I call rather than wait for the next appointment?"
- "Are there other medications I take alongside this one that you want to watch more carefully in relation to kidney function?"
- "Are there baseline labs you recommend before continuing, given my history?"
You do not need to arrive with a diagnosis. Describing what you have noticed and asking what it means gives your provider the specifics they need to help.
How often to check kidney function — and whether additional monitoring is appropriate for you — is a decision your provider makes based on your individual risk profile, existing conditions, and the specific medication you are on. There is no universal monitoring schedule that applies to everyone on a GLP-1 medication.
Providers may order a range of tests to assess kidney function. Interpreting what any result means for your situation is your care team's role, not a determination to make independently.
Tests providers commonly use include eGFR, serum creatinine, uACR, and blood urea nitrogen (BUN). The first three are described in the opening section of this article. BUN is another waste product the kidneys remove from circulating blood; like the others, it requires clinical context to interpret. How often to run any of these tests, and which to prioritize for your situation, is a decision your provider makes based on your full health history.
The information on this page is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your qualified healthcare provider with any questions you may have regarding a medical condition or your medications. Never disregard professional medical advice because of something you read here. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.